

Resource Summary Report

Generated by RRID on Jul 29, 2026

Brilliant Violet 650(TM) anti-human CD3

RRID:AB_2629574

Type: Antibody

Proper Citation

BioLegend Cat# 300468, RRID:AB_2629574

Antibody Information

URL: http://antibodyregistry.org/AB_2629574

Proper Citation: BioLegend Cat# 300468, RRID:AB_2629574

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 650(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_2629574

Vendor: BioLegend

Catalog Number: 300468

Alternative Catalog Numbers: 300467

Record Creation Time: 20250820T041302+0000

Record Last Update: 20250820T182152+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 650(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. *Cancer cell*, 43(2), 269.

He S, et al. (2025) Systemic immune activity occurs during human immune system maturation. *Cell*, 188(25), 7291.

Kaczanowska S, et al. (2024) Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. *Cancer cell*, 42(1), 35.

Yan C, et al. (2023) Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity. *Cancer cell*, 41(7), 1276.

Ke S, et al. (2022) High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer. *iScience*, 25(12), 105529.

Duan LJ, et al. (2022) SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. *Cell reports*, 40(9), 111284.

, et al. (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. *Cell*, 185(5), 916.

Goc J, et al. (2021) Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. *Cell*, 184(19), 5015.

Swanson E, et al. (2021) Simultaneous trimodal single-cell measurement of transcripts, epitopes, and chromatin accessibility using TEA-seq. *eLife*, 10.

Sharma A, et al. (2020) Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. *Cell*, 183(2), 377.